Abstract:The protein transient receptor potential melastatin type 8 (TRPM8), a non-selective, calcium (Ca2+)-permeable ion channel is implicated in several pathological conditions, including neuropathic pain states. In our previous research endeavors, we have identified β-lactam derivatives with high hydrophobic character that exhibit potent and selective TRPM8 antagonist activity. This work describes the synthesis of novel derivatives featuring C-terminal amides and diversely substituted N'-terminal monobenzyl groups in an attempt to increase the total polar surface area (TPSA) in this family of compounds. The primary goal was to assess the influence of these substituents on the inhibition of menthol-induced cellular Ca2+ entry, thereby establishing critical structure-activity relationships. While the substitution of the tert-butyl ester by isobutyl amide moieties improved the antagonist activity, none of the N'-monobencyl derivatives, regardless of the substituent on the phenyl ring, achieved the activity of the model dibenzyl compound. The antagonist potency of the most effective compounds was subsequently verified using Patch-Clamp electrophysiology experiments. Furthermore, we evaluated the selectivity of one of these compounds against other members of the transient receptor potential (TRP) ion channel family and some receptors connected to peripheral pain pathways. This compound demonstrated specificity for TRPM8 channels. To better comprehend the potential mode of interaction, we conducted docking experiments to uncover plausible binding sites on the functionally active tetrameric protein. While the four main populated poses are located by the pore zone, a similar location to that described for the N-(3-aminopropyl)-2-[(3-methylphenyl)methoxy]-N-(2-thienylmethyl)-benzamide (AMTB) antagonist cannot be discarded. Finally, in vivo experiments, involving a couple of selected compounds, revealed significant antinociceptive activity within a mice model of cold allodynia induced by oxaliplatin (OXA).

Analysis of Structure-Activity Relationships for the 'A-Region' of N-(4-T-Butylbenzyl)-N '-[4-(methylsulfonylamino)benzyl]thiourea Analogues As Trpv1 Antagonists

N-[4-(Methylsulfonylamino)benzyl]thiourea Analogues As Vanilloid Receptor Antagonists: Analysis of Structure–activity Relationships for the ‘C-Region’

Analysis of Structure–activity Relationships for the ‘B-Region’ of N -(3-acyloxy-2-benzylpropyl)- N ′ -[4-(methylsulfonylamino)benzyl]thiourea Analogues As Vanilloid Receptor Antagonists: Discovery of an N -Hydroxythiourea Analogue with Potent Analgesic Activity

Analysis of structure-activity relationships with the N-(3-acyloxy-2-benzylpropyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea template for vanilloid receptor 1 antagonism.

<i>N</i>-(3-Acyloxy-2-benzylpropyl)-<i>N</i>‘-[4-(methylsulfonylamino)benzyl]thiourea Analogues: Novel Potent and High Affinity Antagonists and Partial Antagonists of the Vanilloid Receptor

Design, Synthesis and Biological Activities of Benzo[d]imidazo[1,2-A]imidazole Derivatives As TRPM2-specfic Inhibitors

Design, Synthesis and Functional Validation of Peptide Inhibitors Based on TRPV1 Ion Channel Agonist RhTx.

Selective Inhibition of TRPM2 Channel by Two Novel Synthesized ADPR Analogues

A Set of Novel Capsaicin Analogs As Molecular Ruler for Conformational Change of the TRPV1 Ligand-Binding Pocket

Discovery of N -(1,4-Benzoxazin-3-one) urea analogs as Mode-Selective TRPV1 antagonists

Rational Design and Validation of a Vanilloid-Sensitive TRPV2 Ion Channel.

Design, Synthesis and Biological Activities of 2,3-Dihydroquinazolin-4(1h)-one Derivatives As TRPM2 Inhibitors.

In silico research to assist the investigation of carboxamide derivatives as potent TRPV1 antagonists

High Affinity Antagonists of the Vanilloid Receptor.

Structural Pharmacology of TRPV4 Antagonists

β-Lactam TRPM8 Antagonists Derived from Phe-Phenylalaninol Conjugates: Structure-Activity Relationships and Antiallodynic Activity

The Discovery of Novel ACA Derivatives As Specific TRPM2 Inhibitors That Reduce Ischemic Injury Both in Vitro and in Vivo.

High-affinity Partial Agonists of the Vanilloid Receptor.

Discovery of a 4-Aryloxy-1h-pyrrolo[3,2-c]pyridine and a 1-Aryloxyisoquinoline Series of TRPA1 Antagonists

Discovery of N -(1-(2-hydroxyethyl)quinolin-2-one)- N '-(1-phenyl-1H-pyrazol-5-yl)methyl) urea as Mode-Selective TRPV1 antagonist

Structure-activity relationship studies on a series of novel, substituted 1-benzyl-5-phenyltetrazole P2X7 antagonists.